1. Anonymous. FDA warns of serious slowing of the heart rate when the antiarrhythmic drug amiodarone us used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. Available from: www.fda.gov; accessed May 17, 2015.
2. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge;Renet;Gastroenterology,2015
3. Anonymous. IMPORTANT DRUG WARNING. Serious and life-threatening cases of symptomatic bradycardia as well as one case of fatal cardiac arrest reported with coadministration of amiodarone with either Harvoni® (ledipasvir and sofosbuvir fixed-dose combination) or with Sovaldi® (sofosbuvir) in combination with another direct acting antiviral. Dear Healthcare Provider letter. Gilead Sciences, March 20, 2015.
4. A method for estimating the probability of adverse drug reactions;Naranjo;Clin Pharmacol Ther,1981
5. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia;Van Herendael;Vasc Health Risk Manag,2010